Searching journal content for articles similar to Rahaman et al. 23 (12): T211.

Displaying results 1-10 of 1563
For checked items
  1. Research:
    • Shuk-Mei Ho,
    • Rahul Rao,
    • Sarah To,
    • Emma Schoch,
    • and Pheruza Tarapore
    Bisphenol A and its analogues disrupt centrosome cycle and microtubule dynamics in prostate cancer Endocr Relat Cancer 24 (2) 83-96, doi:10.1530/ERC-16-0175 first published on 20 December 2016
    ...is being replaced by these compounds in BPA-free consumer products. We have previously shown that chronic and developmental exposure to BPA is associated with increased prostate cancer (PCa) risk in human and animal models. Here, we examine whether exposure of PCa cells (LNCaP, C4-2) to low-dose BPA...
  2. Review:
    • Gido Snaterse,
    • Jenny A Visser,
    • Wiebke Arlt,
    • and Johannes Hofland
    Circulating steroid hormone variations throughout different stages of prostate cancer Endocr Relat Cancer 24 (11) R403-R420, doi:10.1530/ERC-17-0155 first published on 18 September 2017
    ...estradiol (E2) has risen in recent years, especially as a possible factor in the development of prostate cancer. A shift from apoptosis-inducing estrogen receptor (ER)-β signaling to the growth-stimulatory effects of ER-α during PC evolution suggests a proliferative role of estrogens in advanced disease...
  3. Review:
    • Gianmarco Leone,
    • Marcello Tucci,
    • Consuelo Buttigliero,
    • Clizia Zichi,
    • Daniele Pignataro,
    • Paolo Bironzo,
    • Francesca Vignani,
    • Giorgio Scagliotti,
    • and Massimo Di Maio
    Anti-androgen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer Endocr Relat Cancer ERC-17-0355, doi:10.1530/ERC-17-0355 first published on 28 September 2017
    ..., prostate cancer, bicalutamide, enzalutamide, 9 abiraterone 10 Words: 4167 11 Page 1 of 25 Accepted Preprint first posted on 28 September 2017 as Manuscript ERC-17-0355 Copyright © 2017 by the Society for Endocrinology. Abstract 12 Antiandrogen withdrawal syndrome is an unpredictable event diagnosed...
  4. Thematic Review:
    • Melissa Gamat and
    • Douglas G McNeel
    Androgen deprivation and immunotherapy for the treatment of prostate cancer Endocr Relat Cancer 24 (12) T297-T310, doi:10.1530/ERC-17-0145 first published on 16 August 2017
    ...:12 Thematic Review M Gamat and D G McNeel Androgen deprivation and prostate cancer immunotherapy 10.1530/ERC-17-0145 Melissa Gamat and Douglas G McNeel University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA Abstract Prostate cancer is the most common newly diagnosed malignancy in men...
  5. Research:
    • Zhu Wang,
    • Dinglan Wu,
    • Chi-Fai Ng,
    • Jeremy Yuen-Chun Teoh,
    • Shan Yu,
    • Yuliang Wang,
    • and Franky Leung Chan
    Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer Endocr Relat Cancer ERC-17-0280, doi:10.1530/ERC-17-0280 first published on 17 October 2017
    ...by the networks of specific NRs but also some of these identified orphan NRs could 45 be the potential therapeutic targets for PCSCs or castration-resistant prostate cancer. 46 Page 2 of 38 Introduction 47 It is well established that the normal and neoplastic growth of prostate gland is 48 significantly driven...
  6. Research:
    • Tianzhu Zang,
    • Mary-Ellen Taplin,
    • Daniel Tamae,
    • Wanling Xie,
    • Clementina Mesaros,
    • Zhenwei Zhang,
    • Glenn Bubley,
    • Bruce Montgomery,
    • Steven P Balk,
    • Elahe A Mostaghel,
    • Ian A Blair,
    • and Trevor M Penning
    Testicular vs adrenal sources of hydroxy-androgens in prostate cancer Endocr Relat Cancer 24 (8) 393-404, doi:10.1530/ERC-17-0107 first published on 29 June 2017
    ...& Trabulsi EJ 2010 Hormone therapy in the management of prostate cancer: evidence-based approaches. Therapeutic Advances in Urology 2 171–181. (doi:10.1177/1756287210375270) Huggins C & Hodges CV 2002 Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum...
  7. Research:
    • Masaki Shiota,
    • Akira Yokomizo,
    • Ario Takeuchi,
    • Eiji Kashiwagi,
    • Takashi Dejima,
    • Junichi Inokuchi,
    • Katsunori Tatsugami,
    • Takeshi Uchiumi,
    • and Masatoshi Eto
    Protein kinase C regulates Twist1 expression via NF-κB in prostate cancer Endocr Relat Cancer 24 (4) 171-180, doi:10.1530/ERC-16-0384 first published on 21 February 2017
    ...are now under clinical trials for hematological malignancies (Fuchs 2010). Therefore, it would be intriguing to examine the therapeutic effect of NF-κB inhibitors on castration-resistant and enzalutamide-resistant prostate cancer. In conclusion, NF-κB signaling is responsible for Twist1 upregulation...
  8. Research:
    • Yu-Hsuan Hsiao,
    • Yu-Ting Huang,
    • Chia-Yu Hung,
    • Tzu-Chien Kuo,
    • Fuh-Jinn Luo,
    • and Ta-Chun Yuan
    PYK2 via S6K1 regulates the function of androgen receptors and the growth of prostate cancer cells Endocr Relat Cancer 23 (8) 651-663, doi:10.1530/ERC-16-0122
    ...to cause the malignant transformation of prostate cancer (PCa) cells. Based on the function of AR in PCa progression, inhibition of AR activity is a therapeutic strategy to treat 652Research Y-H Hsiao, Y-T Huang et al. PYK2 regulates AR function in PCa cells DOI: 10.1530/ERC-16-0122 http...
  9. Review:
    • Jennifer Munkley
    Glycosylation is a global target for androgen control in prostate cancer cells Endocr Relat Cancer 24 (3) R49-R64, doi:10.1530/ERC-16-0569 first published on 3 February 2017
    ...a role in synthesising the prostate cancer-associated F77 antigen ( Nonaka et al . 2014 ). The F77 antibody was isolated from mice in 2010 after the injection of PC3 tumour cells and provoked great interest based on its diagnostic and therapeutic potential ( Zhang et al . 2010 ). The F77 antibody...
  10. Thematic Review:
    • Shivangi Agarwal and
    • Dileep Varma
    Targeting mitotic pathways for endocrine-related cancer therapeutics Endocr Relat Cancer 24 (9) T65-T82, doi:10.1530/ERC-17-0080 first published on 14 June 2017
    ...  al. 2004, Seo  et  al. 2005). With regard to endocrine-related cancers, the DNA replication licensing machinery including Cdt1 is emerging as an important therapeutic target to counter prostate cancer (D’Antonio et al. 2009, Majid et al. 2010, McCann et al. 2014, Wang et al. 2014). It is presumable...
For checked items

Search Results

Next 10 » New Search

Modify Results

Citation format:
Results / page:
Results order:

This search

  • Alert me when new articles matching this search are published
  • Download all citations on this page to my citation manager

New Articles: issue in progress

  1. December 2017, 24 (12)
  1. Current Issue
  1. Alert me to new issues of Endocrine-Related Cancer

Most